Home| Journals | Statistics Online Expert | About Us | Contact Us

    About this Journal  | Table of Contents

[Abstract] [PDF] [HTML] [Linked References]

International Journal of Recent Trends in Science and Technology, ISSN 2277-2812 E-ISSN: 2249-8109

Volume 11, Issue 3, July 2014 pp 347-350

Review Article

Incretion based therapy for type 2 diabetes mellitus

Akash Khobragade1, Sadiq Patel2, Nagsen Ramraje3, Ranjit Mankeshwar4, Sagar Bhagat5, Abhijit Bhagat6

{1Assistant Professor, 2Professor and HOD, 5Senior Resident, Department of Pharmacology} {3Professor and HOD, Department Pulmonary Medicine} {4Associate Professor, Department of PSM} Grant Government Medical College and Sir JJ Group of Hospitals, Byculla, Mumbai, Maharashtra, INDIA.

6Assistant Professor, Dept of Pharmacology, MGM’s Medical College and Hospital, Aurangabad, Maharashtra, INDIA.



Most existing antidiabetic agents target only one aspect of the pathophysiology of T2DM, and neither tackle the progressive deterioration in beta-cell mass and function nor the hyperglucagonemia that accompanies T2DM. In contrast, incretin-based approaches target both alpha- and beta-cell dysfunction. Studies indicate that incretin-based therapies perhaps because of the potential trophic effects on the pancreatic beta-cells - may halt the progression of disease that inevitably seems to accompany conventional treatment Within the next year many new and promising GLP-1 analogs and DPP4 inhibitors will be introduced to the market, and, the future will elucidate whether these will have the potential of being disease-modifying drugs.